December 22, 2014
December 18, 2014
Critical Outcome Technologies Inc. Extends Warrants Set to Expire December 20, 2014
December 17, 2014
Critical Outcome Technologies Reports Fiscal 2015 Second Quarter Results
November 27, 2014
November 26, 2014
November 17, 2014
Critical Outcome Technologies Inc. Announces Warrant Term Amendment
November 07, 2014
Critical Outcome Technologies Closes Second Tranche of Financing
October 30, 2014
October 23, 2014
October 23, 2014
October 21, 2014
October 21, 2014
October 17, 2014
October 15, 2014
Critical Outcome Adds a Canadian Patent to COTI-2’s Growing Intellectual Property Portfolio
October 14, 2014
October 06, 2014
October 03, 2014
September 29, 2014
Critical Outcome Technologies’ First Quarter Marked by Key Developments For COTI-2
September 25, 2014
Critical Outcome Technologies Inc. Announces Shareholder Rights Plan and Advance Notice By-law
September 10, 2014
Selective and Potent Anti-Cancer p-53 Dependent Activity Demonstrated by Critical Outcome’s COTI-2
September 8, 2014
August 22, 2014
August 06, 2014
June 23, 2014
Critical Outcome Technologies Seeks to Redefine Personalized Cancer Care with Project Rosalind
June 13, 2014
June 13, 2014
Critical Outcome Technologies Invited to Present at 16th International P53 Workshop in Sweden
June 12, 2014
May 27, 2014
Critical Outcome Technologies Selected to Present at Multiple Investor Conferences in New York City
May 1, 2014
Financing Increases Runway to the Clinic for COTI-2, Critical Outcome’s Lead Cancer Drug Candidate
April 14, 2014
April 4, 2014
March 14, 2014
February 26, 2014
Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
February 6, 2014
